SCHEMBL10312504

SCHEMBL10312504

Cc1ccc2cc(CCC(=O)O[Si](C)(C)C(C)(C)C)ccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
CYP1A2 P05177 3/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAOA P21397 1/20 0.42
SLC6A2 P23975 1/20 0.42
RAB9A P51151 1/20 0.42
SLC6A3 Q01959 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
P2RY12 Q9H244 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
FFAR1 O14842 2/20 0.36
FFAR4 Q5NUL3 2/20 0.36
DRD2 P14416 1/20 0.35
CYP4F2 P78329 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4548367 0.86 CA12 (0.47) LMNACYP1A2MAPTKDM4ENPC1
SCHEMBL10312507 0.81 LMNA (0.46) LMNACYP1A2MAPTKDM4ENPC1
SCHEMBL13535448 0.76 ESRRG (0.40) NPC1MAOARAB9ADRD2CYP4F2
SCHEMBL1205615 0.75 KDM4E (0.44) LMNACYP1A2MAPTKDM4ENPC1
SCHEMBL20323255 0.74 CYP1A2 (0.66) LMNACYP1A2MAPTKDM4ENPC1
SCHEMBL10312503 0.74 FFAR1 (0.57) CYP1A2FFAR1FFAR4ALDH1A1PPARG
SCHEMBL4548366 0.72 CA12 (0.49) LMNACYP1A2MAPTKDM4ENPC1
SCHEMBL21617914 0.70 LMNA (0.60) LMNACYP1A2MAPTKDM4ENPC1
SCHEMBL6545278 0.69 TSHR (0.38) DRD2
SCHEMBL13535450 0.68 FFAR1 (0.47) MAPTKDM4ENPC1TP53RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, FFAR1 LMNA 909/4885CYP1A2 623/4885MAPT 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.